相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
Sara Redaelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Maintenance of Metabolic Homeostasis by Sestrin2 and Sestrin3
Jun Hee Lee et al.
CELL METABOLISM (2012)
Targeting AMPK in the treatment of malignancies
Eliza Vakana et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sestrin2 Modulates AMPK Subunit Expression and Its Response to Ionizing Radiation in Breast Cancer Cells
Toran Sanli et al.
PLOS ONE (2012)
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells
Eliza Vakana et al.
BLOOD (2011)
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
Thomas O'Hare et al.
CLINICAL CANCER RESEARCH (2011)
Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL
Amanda J. Redig et al.
LEUKEMIA & LYMPHOMA (2011)
With TOR, Less Is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging
Pankaj Kapahi et al.
CELL METABOLISM (2010)
FoxOs Inhibit mTORC1 and Activate Akt by Inducing the Expression of Sestrin3 and Rictor
Chia-Chen Chen et al.
DEVELOPMENTAL CELL (2010)
Stressin' Sestrins take an aging fight
Andrei V. Budanou et al.
EMBO MOLECULAR MEDICINE (2010)
Arsenic Trioxide-Dependent Activation of Thousand-and-One Amino Acid Kinase 2 and Transforming Growth Factor-β-Activated Kinase 1
Jennifer L. McNeer et al.
MOLECULAR PHARMACOLOGY (2010)
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes et al.
NATURE MEDICINE (2010)
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
C. A. Sparks et al.
ONCOGENE (2010)
Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
Nathalie Carayol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Sestrin as a Feedback Inhibitor of TOR That Prevents Age-Related Pathologies
Jun Hee Lee et al.
SCIENCE (2010)
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway
R. Naughton et al.
LEUKEMIA (2009)
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
D. Bixby et al.
Hematology-American Society of Hematology Education Program (2009)
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
BLOOD (2008)
Akt Determines Replicative Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells to Oxidative Apoptosis
Veronique Nogueira et al.
CANCER CELL (2008)
p53 target genes Sestrin1 and Sestrin2 connect genotoxic stress and mTOR signaling
Andrei V. Budanov et al.
CELL (2008)
p53 strikes mTORC1 by employing sestrins
Nissim Hay
CELL METABOLISM (2008)
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway
Nathalie Carayol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
Michael G. Kharas et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Applying the discovery of the Philadelphia chromosome
Daniel W. Sherbenou et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Arghya Ray et al.
BLOOD (2007)
Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability
Pavel B. Kopnin et al.
CANCER RESEARCH (2007)
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling
Surinder Kaur et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the AN kinase inhibitor nilotinib (AMN107)
Nikolas von Bubnoff et al.
BLOOD (2006)
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation
M Notari et al.
BLOOD (2006)
Differential regulation of the p70 S6 kinase pathway by interferon αt (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
S Parmar et al.
BLOOD (2005)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
JH Kim et al.
BLOOD (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD
AV Budanov et al.
SCIENCE (2004)
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
MG Mohi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Y Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability
AV Budanov et al.
ONCOGENE (2002)
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells
M Sattler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents
AS Tan et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
分享论文
